Detalhe da pesquisa
1.
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Proc Natl Acad Sci U S A
; 112(11): E1288-96, 2015 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25737542
2.
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Clin Cancer Res
; 24(1): 197-208, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051323
3.
Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Cancer Biol Ther
; 17(1): 27-35, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26575826
4.
DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex.
Oncotarget
; 7(24): 36353-36365, 2016 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27166195
5.
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Cancer Cell
; 29(2): 159-72, 2016 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26859456
6.
Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
PLoS One
; 8(4): e60685, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23577147